title: Genetic resistance to warfarin therapy masked by amiodarone in a 2-year-old girl with mitral valve replacement.
authors.forename: C
authors.initials: C
authors.lastname: Moreau
authors.forename: F
authors.initials: F
authors.lastname: Bajolle
authors.forename: V
authors.initials: V
authors.lastname: Siguret
authors.forename: M-A
authors.initials: MA
authors.lastname: Loriot
authors.forename: D
authors.initials: D
authors.lastname: Bonnet
mesh_terms: D000638:Amiodarone / Q000009:adverse effects / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects*; D002675:Child, Preschool; D002851:Chromatography, High Pressure Liquid; D004347:Drug Interactions; D016903:Drug Monitoring / Q000379:methods; D004351:Drug Resistance / Q000235:genetics*; D005260:Female; D005838:Genotype; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D019934:International Normalized Ratio; D008946:Mitral Valve Stenosis / Q000601:surgery*; D006899:Mixed Function Oxygenases / Q000235:genetics; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D064417:Vitamin K Epoxide Reductases; D014859:Warfarin / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood
chemical_list: D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D014859:Warfarin; D006899:Mixed Function Oxygenases; D064417:Vitamin K Epoxide Reductases; D000638:Amiodarone